CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
所有针对急性淋巴细胞白血病的 CAR-T 治疗都应联合异基因干细胞移植巩固吗？
英文原题：Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant?
查看英文原题
Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
自体T细胞经CD19嵌合抗原受体基因修饰后，是治疗儿童和成人复发/难治性急性淋巴细胞白血病的有效疗法，初始缓解率为70%至85%。遗憾的是，约半数缓解患者随后会复发，这引发了是否应考虑将异基因造血干细胞移植作为巩固治疗的问题。目前，研究重点在于确定复发风险因素，以尝试制定算法，预测哪些患者可能从异基因移植中获益。
展开英文摘要原文
Autologous T cells genetically modified with a CD19 chimeric antigen receptor are an effective therapy for children and adults with relapsed or refractory acute lymphoblastic leukemia with initial response rates ranging from 70 to 85%.
Unfortunately, about half of these responding patients will subsequently relapse raising the question of whether allogeneic hemopoietic stem cell transplant should be considered as a consolidative therapy. Currently efforts are focused on defining risk factors for relapse to try and develop algorithms predicting which patients may benefit from allogenic transplant.
论文信息
- 作者
- Marinos A、Heslop HE
- 第一作者单位
- Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA.United States
- 通讯作者单位
- Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA. Electronic address: hheslop@bcm.edu.United States
- 文献类型
- 综述 · 美国 NIH 资助研究 · 非美国政府资助研究
- 期刊
- Best practice & research. Clinical haematology2022 Dec
- 原文标识
- PubMed 36517124 · DOI 10.1016/j.beha.2022.101414
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →